Aclaris CMO granted 98,100 RSUs and options

Aclaris Therapeutics granted its Chief Medical Officer, Jesse Wayne Hall, new equity awards on February 2, 2026.

Rhea-AI Filing Summary

Aclaris Therapeutics granted its Chief Medical Officer, Jesse Wayne Hall, new equity awards on February 2, 2026. The awards consist of 98,100 restricted stock units, each representing one share of common stock, and an option to purchase 343,300 shares of common stock at an exercise price of $3.61 per share.

Both the restricted stock units and the stock options vest in four equal annual installments on the first, second, third and fourth anniversaries of February 2, 2026, conditioned on Hall’s continued service with the company. Following these grants, Hall directly holds the full reported amounts of these derivative securities.

Insider Trade Summary

Grant/Award: 441,400 shares

Grant/Award 2 txns

Insider Hall Jesse Wayne

Role Chief Medical Officer

Type	Security	Shares	Price	Value
Grant/Award	Restricted Stock Units	98,100	$0.00	$0.00
Grant/Award	Employee Stock Option (Right to Buy)	343,300	$0.00	$0.00

Holdings After Transaction: Restricted Stock Units — 98,100 contracts (Direct); Employee Stock Option (Right to Buy) — 343,300 contracts (Direct)

Footnotes (3)

1. F1. Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer.
2. F2. The shares underlying these restricted stock units vest in four equal installments on the first, second, third and fourth anniversaries of February 2, 2026, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as of each such date.
3. F3. Exercisable with respect to 25% of the shares subject to the option vesting in four equal installments on the first, second, third and fourth anniversaries of February 2, 2026, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as of each such date.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What equity awards did Aclaris Therapeutics (ACRS) grant to its Chief Medical Officer?

Aclaris Therapeutics granted Chief Medical Officer Jesse Wayne Hall 98,100 restricted stock units and an option for 343,300 shares of common stock. The option has a $3.61 exercise price and both awards are subject to multi-year vesting conditions tied to continued service.

When were the new equity awards for Aclaris Therapeutics (ACRS) CMO Jesse Wayne Hall granted?

The equity awards for Jesse Wayne Hall were granted on February 2, 2026. On that date he received 98,100 restricted stock units and a stock option for 343,300 shares at a $3.61 exercise price, all subject to future vesting requirements over four years.

How do the restricted stock units for Aclaris Therapeutics (ACRS) CMO vest?

The 98,100 restricted stock units vest in four equal installments on the first, second, third, and fourth anniversaries of February 2, 2026. Vesting requires Hall to maintain “Continuous Service” under the company’s plan on each applicable vesting date.

What are the key terms of the Aclaris Therapeutics (ACRS) stock option granted to its CMO?

The stock option covers 343,300 shares of Aclaris common stock at an exercise price of $3.61 per share. It becomes exercisable in four equal annual installments starting on the first anniversary of February 2, 2026, contingent on Hall’s continued service.

How many derivative securities does Aclaris Therapeutics (ACRS) CMO hold after the reported Form 4 transactions?

After the reported grants, Jesse Wayne Hall directly holds 98,100 restricted stock units and a stock option for 343,300 shares. These holdings are derivative securities linked to Aclaris common stock and will deliver or permit purchase of shares as they vest or become exercisable.

What does each restricted stock unit for Aclaris Therapeutics (ACRS) represent in the CMO’s grant?

Each restricted stock unit represents a contingent right to receive one share of Aclaris common stock. Delivery of those shares depends on the RSUs vesting over four annual installments and on Jesse Wayne Hall satisfying the plan’s “Continuous Service” requirement on each vesting date.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/06/2026 - 06:04 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Hall Jesse Wayne

(Last) (First) (Middle)

C/O ACLARIS THERAPEUTICS, INC.

701 LEE ROAD, SUITE 103

(Street)

WAYNE PA 19087

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Aclaris Therapeutics, Inc. [ ACRS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Medical Officer

3. Date of Earliest Transaction (Month/Day/Year)
02/02/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units	(1)	02/02/2026		A		98,100		(2)	(2)	Common Stock	98,100	$0	98,100	D
Employee Stock Option (Right to Buy)	$3.61	02/02/2026		A		343,300		(3)	02/01/2036	Common Stock	343,300	$0	343,300	D

Explanation of Responses:

1. Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer.

2. The shares underlying these restricted stock units vest in four equal installments on the first, second, third and fourth anniversaries of February 2, 2026, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as of each such date.

3. Exercisable with respect to 25% of the shares subject to the option vesting in four equal installments on the first, second, third and fourth anniversaries of February 2, 2026, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as of each such date.

	/s/ Matthew Rothman, Attorney-in-Fact	02/06/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.